中牧实业股份有限公司董事会 公司独立董事符合《上市公司独立董事管理办法》《上海证券交 易所上市公司自律监管指引第 1 号—规范运作》等法律法规中关于独 立董事任职资格及独立性的要求，不存在任何妨碍其进行独立客观判 断的关系，不存在影响独立董事独立性的情况。 中牧实业股份有限公司董事会 2025 年 4 月 10 日 关于对独立董事独立性自查情况的专项报告 根据《上市公司独立董事管理办法》《上海证券交易所上市公司 自律监管指引第 1 号—规范运作》等要求，并结合独立董事出具的《中 牧实业股份有限公司独立董事关于独立性情况的自查报告》，中牧实 业股份有限公司(以下简称"公司")董事会就公司在任独立董事唐功 远、谯仕彦、胡燕的独立性情况进行评估并出具如下专项意见： ...

召开地点：北京市丰台区南四环西路 188 号总部基地 8 区 16 号楼 8 层公司 会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 5 月 13 日 股票代码：600195 股票简称：中牧股份 公告编号：2025-008 中牧实业股份有限公司 关于召开2024年年度股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 召开的日期时间：2025 年 5 月 13 日 13 点 30 分 本次股东会还将听取独立董事 2024 年度述职报告。 至2025 年 5 月 13 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过互联 网投票平台的投票时间为股东会召开当日的 9:15-15:00。 股东会召开日期：2025年5月13日 本次股东会采用的网络投票系统：上海证券交易所股 ...

股票代码：600195 股票简称：中牧股份 编号：临 2025-006 中牧实业股份有限公司 第九届监事会第一次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 中牧实业股份有限公司（以下简称"公司"或"中牧股份"）第九届监事会第一 次会议通知于 2025 年 3 月 28 日通过公司电子办公系统、电子邮件等形式发出，会 议于 2025 年 4 月 10 日在北京市丰台区总部基地八区 16 号楼 801 会议室以现场结合 视频的方式召开，会议应到监事 3 名，实到监事 3 名。会议由监事会主席侯士忠先 生主持，符合《公司法》《公司章程》的规定。 经与会监事认真审议，会议表决通过如下议案： 一、中牧股份 2024 年度监事会工作报告 表决结果：3 票同意，0 票反对，0 票弃权。 报告期内，监事会认真审阅了 2024 年度内的定期报告并出具了书面审核意见。 经审阅，监事会认为公司 2024 年度内的定期报告的编制和审议程序均符合法律、法 规、《公司章程》和公司内部管理制度的各项规定；内容和格式均符合中国证监会和 上海 ...

股票代码：600195 股票简称：中牧股份 编号：临 2025-005 中牧实业股份有限公司 第九届董事会第一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 中牧实业股份有限公司（以下简称"公司"或"中牧股份"）第九届董事会第 一次会议通知于 2025 年 3 月 28 日通过公司电子办公系统、电子邮件等形式发出， 会议于 2025 年 4 月 10 日在北京市丰台区总部基地八区 16 号楼 801 会议室以现场 结合视频的方式召开，会议应到董事 6 名，实到董事 6 名。公司监事、高管人员列 席本次会议。会议由董事长吴冬荀先生主持，符合《公司法》《公司章程》的规定。 经与会董事审议，会议表决通过如下议案： 一、中牧股份 2024 年度董事会工作报告 本报告在提交董事会前已经公司董事会审计委员会审议通过。 表决结果：6 票同意，0 票反对，0 票弃权。 该报告需提交公司 2024 年年度股东会审议。 二、中牧股份 2024 年度总经理工作报告 表决结果：6 票同意，0 票反对，0 票弃权。 三、中牧股份董事会审 ...

股票代码：600195 股票简称：中牧股份 编号：临 2025-007 如在本公告披露之日起至实施权益分派的股权登记日期间，因可转债转股、回 购股份、股权激励授予股份回购注销、重大资产重组股份回购注销等致使公司总股 本发生变动的，公司拟维持现金分红总额不变，相应调整每股分配比例。如后续总 股本发生变动，公司将另行公告具体调整情况。 中牧实业股份有限公司 2024 年度利润分配预案公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、利润分配预案内容 （一）利润分配预案的具体内容 经天健会计师事务所（特殊普通合伙）审计，截至 2024 年 12 月 31 日，公司 母公司报表中期末未分配利润为 2,771,271,035.53 元。经董事会决议，公司 2024 年 年度拟以实施权益分派股权登记日登记的总股本为基数分配利润。本次利润分配预 案如下： 公司拟向全体股东每股派发现金红利 0.023 元（含税）。截至 2024 年 12 月 31 日，公司总股本 1,021,148,260 股，以此计算合计拟派发现金 ...

Financial Performance - The company's operating revenue for 2024 reached CNY 6,017,190,375.67, an increase of 11.30% compared to CNY 5,406,312,590.46 in 2023[21] - The net profit attributable to shareholders of the listed company was CNY 70,884,445.64, a decrease of 82.41% from CNY 403,051,611.99 in the previous year[21] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 62,137,902.01, down 77.72% from CNY 278,858,364.79 in 2023[21] - The net cash flow from operating activities was CNY 419,565,593.23, an increase of 12.65% compared to CNY 372,461,428.84 in 2023[21] - Basic earnings per share decreased by 82.42% to CNY 0.0694 compared to CNY 0.3947 in 2023[22] - Net profit attributable to shareholders decreased by 82.41% due to a decline in gross profit and investment income[22] - The weighted average return on equity decreased by 6.17 percentage points to 1.29% from 7.46% in 2023[22] Assets and Liabilities - The total assets at the end of 2024 were CNY 8,843,999,066.31, a decrease of 1.14% from CNY 8,946,377,928.42 at the end of 2023[21] - The net assets attributable to shareholders of the listed company were CNY 5,505,042,539.52, a slight decrease of 0.28% from CNY 5,520,675,866.70 at the end of 2023[21] - The company reported a net cash outflow from financing activities of ¥496,179,946.71, a significant decrease of 165.34% compared to the previous year, primarily due to increased cash used for debt repayment[46] - The accounts payable increased by 291.84% to ¥255,443,942.00, indicating a rise in external payment obligations[59] Dividends and Shareholder Returns - The company plans to distribute a cash dividend of CNY 0.23 per 10 shares, totaling CNY 23,486,409.98, based on a total share capital of 1,021,148,260 shares[6] - The cash dividend distribution for the year 2023 is set at 0.119 yuan per share, totaling approximately 121.52 million yuan, which represents about 30.15% of the net profit attributable to shareholders[146] - The cumulative cash dividend amount over the last three accounting years is approximately 328.81 million yuan, with a cash dividend ratio of 96.33% based on the average annual net profit[151] Research and Development - The company is committed to high-quality development and innovation as part of its strategic goals for the "14th Five-Year Plan" period[32] - R&D expenses increased by 17.13% to ¥143,898,523.68, primarily due to higher direct material and testing costs associated with R&D projects[46] - Total R&D investment amounted to ¥159,306,758.78, representing 2.65% of operating revenue[54] - The number of R&D personnel is 468, accounting for 11% of the total workforce[55] - The company is actively involved in the research and development of various vaccines, including a rabies inactivated vaccine and a vaccine for pseudorabies in pigs[71] Market and Product Development - The company achieved a significant market share in key products such as foot-and-mouth disease vaccine and ST pig fever vaccine, with a focus on large clients and major products[32] - The company is actively expanding its product offerings in the pet market, integrating various marketing strategies and accelerating product development[34] - The company is expanding its product offerings in pet nutrition and health products[73] - The company plans to expand its international market presence as part of its "Belt and Road" initiative, enhancing competitiveness[100] Corporate Governance and Compliance - The company emphasizes that forward-looking statements in the report do not constitute substantive commitments to investors, highlighting potential investment risks[7] - The company has received a standard unqualified audit report from Tianjian Accounting Firm[5] - The company is committed to enhancing corporate governance and compliance with legal regulations, ensuring no insider trading incidents occurred during the reporting period[112] - The company’s audit committee emphasized the importance of independent and objective auditing practices, contributing to improved corporate governance and internal control[131] Environmental and Social Responsibility - The company invested approximately ¥29.83 million in environmental protection during the reporting period[157] - The company has implemented comprehensive pollution prevention measures, ensuring that all wastewater and waste gas meet discharge standards[160] - Total investment in poverty alleviation and rural revitalization projects amounted to 1.32 million CNY, with 1.1 million CNY allocated for targeted assistance in Xiaoxian County[175] - The company donated a total of 150,000 CNY to charity initiatives, including 100,000 CNY for the "Charity One Day Donation" event in Linyi City[174] Strategic Planning and Future Outlook - The company aims to enhance its position as a leader in the animal health and feed additive industry, focusing on green development and innovation[99] - The company plans to balance traditional industry upgrades with the development of strategic emerging industries to enhance competitiveness and resilience in the supply chain[105] - The company will strengthen risk prevention measures to ensure safety in development and maintain national security responsibilities[107] - The company provided a positive outlook for the next quarter, projecting a revenue increase of 25% to 1.875 billion RMB[119]

中牧股份（600195）公告，2024年营业收入60.17亿元，同比增长11.30%。归属于上市公司股东的净利 润7088.44万元，同比下降82.41%。向全体股东每10股派发现金红利0.23元，共计派发现金红利2348.64 万元。 ...

Core Insights - The global animal vaccine market is projected to exceed $14 billion in 2024, following a market size of over $13.5 billion in 2023, with a compound annual growth rate (CAGR) of 10.10% over the past five years [1][8]. Market Overview - Animal vaccines, also known as veterinary vaccines, are products made from pathogenic microorganisms that stimulate the immune system of animals to produce specific antibodies, thereby preventing infectious diseases [1]. - North America, including the United States and Canada, is the largest regional market for animal vaccines, accounting for approximately 45% of the global market share in 2023 [3]. Industry Competition - Leading companies in the global animal vaccine industry offer a diverse range of products, including vaccines for pets, pigs, poultry, ruminants, and aquaculture [5]. - Major players such as Merck Animal Health, Zoetis, and Boehringer Ingelheim have established multiple production bases worldwide, indicating significant production capacity [5]. Company Profiles - **Merck Animal Health**: Offers pet vaccines, pig vaccines, poultry vaccines, and aquaculture vaccines, with 29 production bases across 12 countries, including a major facility in Suzhou, China [6]. - **Zoetis**: Operates production bases in the United States and China, having established its first R&D and production base in China in 2019 [6]. - **Boehringer Ingelheim**: Maintains over 20 production bases globally, with two facilities located in Nanchang and Taizhou, China [6]. - **Hualan Biological Engineering**: Initially focused on blood products, it has become a major producer of influenza vaccines in China, accounting for over 40% of the national market [6]. - **Fubao Animal Health**: Produces vaccines for pigs, poultry, and aquaculture, with production bases in the United States and Suzhou, China [6].

Market Overview - The A-share market indices have collectively risen, driven by multiple favorable factors [1] - The "Zhong" stocks, particularly those with "Zhong" in their names, have seen significant gains, with several stocks reaching their daily limit [1] Key Stock Performances - Zhongcang Co. (600787) opened strongly and reached the daily limit within 20 minutes, closing at a 10.07% increase [2] - Zhongfangbiao (873122) surged by 22.24%, while Zhongliang Kegong (301058) increased by 20.04% [2] - Other notable performers include Zhongtie Zhuangpei (300374) with an 11.37% rise, and China Tonghao (688009) with a 10.04% increase [2][3] Sector Analysis - The "Zhong" stocks have shown robust performance, with many stocks in this category experiencing gains of over 5% [1][2] - The retail sector has also attracted significant capital inflow, with net inflows exceeding 1 billion yuan in various segments, including community group buying and unified market [9] - The banking sector has seen a rebound, with several banks, including Pudong Development Bank, rising over 5% [11][12] ETF Activity - The trading volume for broad-based ETFs has continued to increase, with the CSI 300 ETF (510300) exceeding 12.1 billion yuan in trading volume [16] - Other ETFs, such as the CSI 500 ETF (510500), also reported significant trading volumes, indicating strong investor interest [16]

同意中牧实业股份有限公司 2025 年度投资计划。 二、关于调整、更名公司部分组织机构的议案 表决结果：6 票同意，0 票反对，0 票弃权。 股票代码：600195 股票简称：中牧股份 编号：临 2025-004 中牧实业股份有限公司 第九届董事会 2025 年第四次临时会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 中牧实业股份有限公司（以下简称"公司"）第九届董事会 2025 年第四次临时 会议通知于 2025 年 3 月 24 日通过公司电子办公系统、电子邮件等形式发出，会议 于 2025 年 3 月 27 日以通讯方式召开，会议应到董事 6 名，实到董事 6 名。会议由 董事长吴冬荀先生主持，符合《公司法》《公司章程》的规定。 会议审议并通过以下事项： 一、中牧实业股份有限公司 2025 年度投资计划 表决结果：6 票同意，0 票反对，0 票弃权。 根据公司战略规划和业务经营管理需要，同意成立国际业务发展部，同意将战 略运营部与投资管理部合并，成立战略投资部，同时相应调整部门职责定位；同意 新业务发展部更 ...